Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass
- 1 August 1999
- journal article
- research article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 68 (2) , 473-478
- https://doi.org/10.1016/s0003-4975(99)00551-2
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Heart, Lung, and Blood Institute
This publication has 23 references indexed in Scilit:
- Aprotinin for Primary Coronary Artery Bypass Grafting: A Multicenter Trial of Three Dose RegimensThe Annals of Thoracic Surgery, 1996
- Pericardial Blood Activates the Extrinsic Coagulation Pathway During Clinical Cardiopulmonary BypassCirculation, 1996
- A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass GraftingCirculation, 1995
- AprotininDrugs, 1995
- Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complexThrombosis Research, 1993
- Tissue factor is expressed on monocytes during simulated extracorporeal circulation.Circulation Research, 1993
- Topical use of aprotinin in open heart operationsThe Annals of Thoracic Surgery, 1993
- Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activationBlood, 1993
- Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled studyThe Annals of Thoracic Surgery, 1992
- Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(- )-inhibitor complexes in sepsisBlood, 1988